SIGHT GenSight Biologics S.A.

EPA · FR · Healthcare · Biotechnology · gensight-biologics.com

0.0801EUR-4.30%Mkt Cap: 20.42M $P/E: —Today

GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company deve…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap20.42M USD

Enterprise Value30.82M USD

Revenue (TTM)-272.83K USD

Gross Profit-272.83K USD

Net Income (TTM)-13.08M USD

Revenue/Share-0.0010 EUR

Last Price0.0801 EUR

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees13

CountryFR

SectorHealthcare

IndustryBiotechnology

ISINFR0013183985

Valuation

P/E (Trailing)—

P/E (Forward)-0.10

PEG—

EV/EBITDA-2.23

EV/Revenue-112.98

P/S-78.20

P/B-0.74

EPS (TTM)-0.08

EPS (Forward)-0.81

52W Range

0.07155% of range0.2390

52W High0.2390 EUR

52W Low0.0715 EUR

Profitability

Gross Margin0.00%

Oper. Margin996.85%

EBITDA Margin0.00%

Profit Margin-1203600.00%

ROE48.26%

ROA-145.78%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-9.97M USD

CapEx (TTM)4.35K USD

FCF Margin5332.77%

FCF Yield-71.26%

Net Debt12.14M USD

Net Debt/EBITDA-0.88

Balance Sheet

Debt/Equity-0.52

Current Ratio0.35

Quick Ratio0.14

Book Value/Sh-0.11 EUR

Cash/Share0.0080 EUR

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 EUR

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating—

Target (Mean)0.3050 EUR

Upside (mean)+280.8%

Target Range0.2100 EUR – 0.4000 EUR

0.2100+280.8% to mean0.4000

# Analysts2

Ownership

Shares Out.234.52M

Float157.13M

Insiders7.07%

Institutions41.19%

Technical

SMA 500.1051 (-23.8%)

SMA 2000.0906 (-11.6%)

Beta—

S&P 52W Chg14.58%

Avg Vol (30d)1.82M

Avg Vol (10d)2.15M

Technical Indicators

RSI (14)32.1

MACD-0.0024

MACD Signal0.0019

MACD Hist.-0.0043

BB Upper0.1354 EUR

BB Middle0.1118 EUR

BB Lower0.0882 EUR

BB Width42.18%

ATR (14)0.0089 EUR

Vol Ratio (20d)2.27x